Amphastar Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Amphastar Pharmaceuticals' es Jack Zhang , nombrado en Jan 1996, tiene una permanencia de 28.25 años. compensación anual total es $7.72M, compuesta por 11.6% salario y 88.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.58% de las acciones de la empresa, por valor de $91.76M. La antigüedad media del equipo directivo y de la junta directiva es de 10.4 años y 4.8 años, respectivamente.
Información clave
Jack Zhang
Chief Executive Officer (CEO)
US$7.7m
Compensación total
| Porcentaje del salario del CEO | 11.6% |
| Permanencia del CEO | 28.3yrs |
| Participación del CEO | 4.6% |
| Permanencia media de la dirección | 10.5yrs |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13Amphastar Pharma: A Well-Run, Diversified Mid Cap
Jan 26Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?
Jan 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
Compensación vs. Mercado: La compensación total de Jack($USD7.72M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Jack ha sido consistente con los resultados de la empresa en el último año.
CEO
Jack Zhang (76 yo)
28.3yrs
Permanencia
US$7,722,768
Compensación
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 28.3yrs | US$3.77m | 2.35% $ 48.9m | |
| Co-founder | 28.3yrs | US$7.72m | 4.58% $ 95.5m | |
| CFO, Executive VP of Finance | 10.1yrs | US$2.89m | 0.081% $ 1.7m | |
| Executive VP of Sales | 10.9yrs | US$1.78m | 0.093% $ 1.9m | |
| Senior Executive Vice President of Production | 8.9yrs | US$2.03m | 0.38% $ 8.0m | |
| Vice President of Human Resources & Corporate Communication | 1.8yrs | sin datos | sin datos | |
| Senior VP of Regulatory Affairs & Clinical Operations | no data | sin datos | sin datos |
10.5yrs
Permanencia media
64yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AMPH es experimentado (10.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 28.3yrs | US$3.77m | 2.35% $ 48.9m | |
| Co-founder | 28.3yrs | US$7.72m | 4.58% $ 95.5m | |
| CFO, Executive VP of Finance | 1.8yrs | US$2.89m | 0.081% $ 1.7m | |
| Executive VP of Sales | 1.8yrs | US$1.78m | 0.093% $ 1.9m | |
| Lead Independent Director | 22.3yrs | US$362.00k | 0.058% $ 1.2m | |
| Independent Director | 2.9yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.9yrs | US$314.70k | 0.026% $ 547.8k |
4.9yrs
Permanencia media
64.5yo
Promedio de edad
Junta con experiencia: La junta directiva de AMPH se considera experimentada (4.8 años de antigüedad promedio).